LiSyM: The better way to manage your data
Free and open platform for easier research data management
Latest additions
Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1
Publication - added 7 days agoSerum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B
Publication - added 7 days agoFOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression
Publication - added 7 days agoA hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditions
Publication - added 7 days agoTransforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease
Publication - added 7 days agoFollistatin‐controlled activin‐HNF4α‐coagulation factor axis in liver progenitor cells determines outcome of acute liver failure
Publication - added 7 days agoDigital twin demonstrates significance of biomechanical growth control in liver regeneration after partial hepatectomy
Publication - added 7 days agoSolid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors
Publication - added 12 days agoCOMBINE 2022 (Computational Modeling in Biology Network Meeting)
Event - added 13 days agoDiploid hepatocytes drive physiological liver renewal in adult humans
Publication - added 13 days ago
Find content
LiSyM (Liver Systems Medicine) represents a research network of German centers and institutions, brought together by a 20 Million Euro funding program of the German Government, in which mathematicians, modelers, pharmacologists, molecular biologists and clinical scientists work together to develop a Systems Medicine approach to study early and advanced liver disease.
The aim of this unique research program is to acquire and use new experimental data and data from existing data bases to build computational models that facilitate decision making at the patient's bedsite and to predict the actions of new medicines in the treatment of metabolic liver disease.